Cognoa, Inc.

Cognoa, Inc. is a healthcare technology company dedicated to developing digital diagnostics and therapeutics aimed at enhancing early childhood development and pediatric behavioral health. Cognoa was founded in 2014 and is headquartered in Palo Alto, US. The company specializes in digital solutions for pediatric behavioral health, including its flagship product, Canvas Dx, which enables timely autism diagnosis.

The founder, Dennis Wall, has a background in technology and healthcare innovation. In February 2017, Cognoa raised USD 11. 6 mn in Series A funding from Morningside Private Investors, which contributed to a total amount raised of USD 11. 6 mn and a current valuation of USD 24.

89 mn. Cognoa has completed 2 deals since its inception. Cognoa specializes in developing digital diagnostics and therapeutics focused on early childhood development and pediatric behavioral health. Their flagship product, Canvas Dx, is the first and only FDA-authorized diagnostic solution designed to enable clinicians to diagnose or rule out autism in children aged 1.

5 to 6 years within days, rather than months or years. This innovative solution utilizes a remote, digital evaluation process, allowing access to care for children in underserved areas and reducing the burden on oversubscribed specialty centers. The company aims to address significant delays in autism diagnosis, which typically occurs after the age of four, by providing an objective, data-driven approach that enhances diagnostic accuracy and mitigates biases. Cognoa's products are primarily deployed in the United States, targeting healthcare professionals, families, and caregivers who seek timely and equitable autism diagnosis and intervention.

Cognoa generates revenue through the deployment of its diagnostic solutions, notably Canvas Dx, which has gained reimbursement coverage from insurance providers such as Highmark Insurance. The company’s transaction structure is primarily B2B, as it partners with healthcare professionals who utilize the Canvas Dx solution in clinical settings. By establishing direct relationships with clinicians, Cognoa facilitates access to its diagnostic tools, which can be integrated into existing practice workflows. The revenue model is designed to support clinicians in diagnosing autism efficiently, ultimately aiming to improve patient outcomes.

The pricing structure for the services is aligned with typical healthcare reimbursement frameworks, ensuring that practitioners can offer the diagnostic solution to families without financial barriers. Cognoa plans to utilize the recent Series A funding of USD 11. 6 mn to support the development and launch of upcoming products that enhance early childhood behavioral health diagnostics. The company aims to expand its market presence in additional geographic regions, targeting healthcare networks across the US and potentially exploring international markets by 2025.

This strategic expansion is designed to increase access to their diagnostics and therapeutics, better serving the needs of families and healthcare providers in addressing pediatric behavioral health issues.